GRTX Stock Price, Galera Therapeutics Inc Quote, Chart

Market Summary

USD0.19+0.01

Delayedas of 22 Apr 2024, 01:05 pm

5.56%

GRTX Alerts

1 major insider sales recently.

GRTX Stock Price

View Fullscreen

GRTX RSI Chart

GRTX Valuation

Market Cap

9.8M

Price/Earnings (Trailing)

-0.17

EV/EBITDA

0.17

Price/Free Cashflow

-0.22

MarketCap/EBT

-0.17

GRTX Price/Sales (Trailing)

GRTX Profitability

Return on Equity

45.04%

Return on Assets

-226.01%

Free Cashflow Yield

-458.68%

GRTX Fundamentals

GRTX Earnings

Earnings (TTM)

-59.1M

Earnings Growth (Yr)

65.49%

Earnings Growth (Qtr)

62.93%

Breaking Down GRTX Revenue

52 Week Range

0.173.59

(Low)(High)

Last 7 days

18.8%

Last 30 days

-20.8%

Last 90 days

11.8%

Trailing 12 Months

-93.2%

How does GRTX drawdown profile look like?

GRTX Financial Health

Current Ratio

4.36

GRTX Investor Care

Shares Dilution (1Y)

26.77%

Diluted EPS (TTM)

-0.95

Tracking the Latest Insider Buys and Sells of Galera Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 28, 2024	altamont pharmaceutical holdings, llc	sold	-101,120	0.1459	-693,076	-
Mar 27, 2024	altamont pharmaceutical holdings, llc	sold	-52,146	0.1699	-306,924	-
Mar 26, 2024	altamont pharmaceutical holdings, llc	sold	-393,000	0.1965	-2,000,000	-
Mar 25, 2024	altamont pharmaceutical holdings, llc	sold	-170,742	0.2189	-780,000	-
Mar 22, 2024	altamont pharmaceutical holdings, llc	sold	-4,600	0.23	-20,000	-
Feb 08, 2024	schneid yair	bought	25,650	0.171	150,000	-
Feb 07, 2024	schneid yair	bought	30,185	0.172486	175,000	-
Feb 06, 2024	schneid yair	bought	5,025	0.201	25,000	-
Feb 05, 2024	schneid yair	bought	17,922	0.184	97,402	-
Jan 30, 2024	schneid yair	bought	60,635	0.181	335,000	-

Which funds bought or sold GRTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	MANCHESTER FINANCIAL INC	added	227	6,881	10,080	-%
Apr 03, 2024	WealthCollab, LLC	new	-	570	570	-%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-57.58	-119,872	65,187	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	sold off	-100	-2,097	-	-%
Feb 26, 2024	Virtu Financial LLC	added	359	6,000	8,000	-%
Feb 16, 2024	GSA CAPITAL PARTNERS LLP	new	-	566,000	566,000	0.05%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	1,659	1,659	-%
Feb 14, 2024	STATE STREET CORP	unchanged	-	-3,165	15,494	-%
Feb 14, 2024	GROUP ONE TRADING, L.P.	unchanged	-	-1,927	9,436	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	reduced	-37.5	-68.00	72.00	-%

Are Funds Buying or Selling GRTX?

Are funds buying GRTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GRTX

No. of Funds

GRTX Alerts

1 major insider sales recently.

Unveiling Galera Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 16, 2024	alpha pharma investments llc	5.05%	11	SC 13G
Apr 03, 2024	altamont pharmaceutical holdings, llc	0%	0	SC 13G/A
Feb 20, 2024	sofinnova venture partners ix, l.p.	10.0%	0	SC 13D/A
Feb 14, 2024	sectoral asset management inc	0%	0	SC 13G/A
Jan 17, 2024	schneid yair	073%	7,110,801	SC 13G
Jan 02, 2024	gsa capital partners llp	156%	3,892,561	SC 13G
Dec 04, 2023	blackstone holdings i/ii gp l.l.c.	1.0%	542,555	SC 13D/A
Nov 13, 2023	altamont pharmaceutical holdings, llc	12.02%	5,280,000	SC 13G
Jun 28, 2023	novo holdings a/s	4.9%	2,100,000	SC 13G/A
Feb 28, 2023	flynn james e	4.99%	2,916,401	SC 13G

Recent SEC filings of Galera Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 16, 2024	SC 13G	Major Ownership Report
Apr 03, 2024	SC 13G/A	Major Ownership Report
Apr 01, 2024	5	Insider Trading
Mar 28, 2024	8-K	Current Report
Mar 28, 2024	10-K	Annual Report
Mar 27, 2024	8-K	Current Report
Feb 26, 2024	4	Insider Trading
Feb 20, 2024	SC 13D/A	13D - Major Acquisition
Feb 14, 2024	SC 13G/A	Major Ownership Report
Jan 17, 2024	SC 13G	Major Ownership Report

Peers (Alternatives to Galera Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	38.7B	6.8B	-1.66%	-28.18%	-8.22	5.66	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.2B	1.8B	-2.46%	-28.84%	-41.3	9.94	76.23%	61.08%
BMRN	16.7B	2.4B	4.57%	-8.46%	99.75	6.91	15.42%	18.43%
INCY	11.8B	3.7B	-10.11%	-29.11%	19.67	3.18	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-14.37%	-42.33%	-10.84	14.45	425.83%	18.94%
BBIO	4.4B	-	-13.59%	50.21%	-6.66	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-13.81%	-4.67%	-13.45	11.89	440.80%	-27.84%
ACAD	2.8B	726.4M	-9.91%	-15.82%	-45.22	3.82	40.45%	71.62%
ARWR	2.8B	240.7M	-20.67%	-25.33%	-9.32	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-10.64%	-8.42%	24.94	4.47	85.90%	-14.05%
NVAX	558.4M	983.7M	-17.39%	-51.52%	-1.02	0.57	-50.36%	17.16%
CRBP	409.4M	881.7K	-0.38%	387.14%	-9.18	466.16	-77.61%	-5.33%
INO	226.2M	4.9M	-10.29%	-2.81%	-1.67	46.49	-54.97%	51.71%
IBIO	6.0M	2.1M	59.81%	33.59%	-0.22	2.14	-13.45%	66.37%

Galera Therapeutics Inc News

Latest updates

Galera Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																			(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Assets	-30.8%	26.00	38.00	48.00	60.00	44.00	51.00	61.00	71.00	83.00	99.00	115	70.00	84.00	98.00	114	131	123	80.00	88.00
Current Assets	-30.8%	22.00	31.00	42.00	54.00	39.00	45.00	55.00	65.00	77.00	93.00	109	64.00	78.00	92.00	108	125	118	72.00	84.00
Cash Equivalents	-25.1%	18.00	24.00	24.00	26.00	4.00	13.00	17.00	20.00	20.00	18.00	38.00	14.00	16.00	15.00	16.00	22.00	18.00	16.00	15.00
Net PPE	-64.1%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Goodwill	0%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	-4.3%	157	164	163	157	153	148	144	142	141	142	141	81.00	78.00	73.00	74.00	78.00	54.00	52.00	27.00
Current Liabilities	-60.8%	5.00	13.00	14.00	13.00	13.00	12.00	11.00	11.00	13.00	16.00	17.00	16.00	14.00	11.00	12.00	13.00	10.00	9.00	6.00
Shareholder's Equity	-Infinity%	-131	-	-	-	-109	-	-	-	-58.00	-	-	-	6.00	25.00	40.00	53.00	70.00	-	-
Retained Earnings	-1.3%	-437	-431	-416	-396	-378	-362	-346	-331	-316	-299	-276	-254	-235	-215	-198	-179	-161	-144	-104
Additional Paid-In Capital	0.3%	306	305	302	298	269	265	263	261	258	256	251	244	242	240	238	232	231	-	-
Shares Outstanding	1.2%	54.00	54.00	44.00	43.00	29.00	27.00	27.00	27.00	26.00	26.00	25.00	25.00	-	-	-	-	-	-	-
Float	-	-	-	130	-	-	-	32.00	-	-	-	162	-	-	-	112	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	20.8%	-9,915	-12,521	-10,746	-11,666	-13,945	-9,210	-8,886	-11,385	-17,446	-18,404	-16,805	-15,303	-16,450	-15,284	-15,411	-12,392	-15,276	-12,901	-9,555	-8,929	-
Share Based Compensation	-14.6%	1,187	1,390	1,525	1,458	1,736	1,750	1,830	1,848	1,959	1,870	1,611	1,791	1,368	1,505	1,453	1,210	806	520	565	499	-
Cashflow From Investing	-62.0%	3,975	10,464	7,549	5,305	2,779	4,604	6,615	9,996	19,651	-43,041	15,745	12,883	16,858	14,410	9,674	-4,395	-41,790	12,770	-1,401	2,596	-
Cashflow From Financing	-110.9%	-232	2,134	1,812	27,782	2,702	10.00	2.00	1,175	22.00	40,612	25,838	235	232	224	41.00	20,009	59,703	-345	-	-	-

GRTX Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 24,115	$ 31,012
General and administrative	22,836	20,214
Restructuring costs	2,309	0
Loss from operations	(49,260)	(51,226)
Other income (expenses):
Interest income	1,595	506
Interest expense	(11,414)	(11,571)
Foreign currency loss	(3)	(1)
Loss before income tax benefit	(59,082)	(62,292)
Income tax benefit	0	70
Net loss	$ (59,082)	$ (62,222)
Net loss per share of common stock, basic	$ (1.33)	$ (2.3)
Net loss per share of common stock, diluted	$ (1.33)	$ (2.3)
Weighted-average shares of common stock outstanding, basic	44,549,285	27,086,664
Weighted-average shares of common stock outstanding, diluted	44,549,285	27,086,664

GRTX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 18,257	$ 4,266
Short-Term Investments	0	27,331
Restricted cash	0	50
Refundable PDUFA fee	0	3,242
Prepaid expenses and other current assets	3,372	3,646
Total current assets	21,629	38,535
Property and equipment, net	71	438
Acquired intangible asset	2,258	2,258
Goodwill	881	881
Right-of-use lease assets	1,212	43
Other assets	90	1,881
Total Assets	26,141	44,036
Current Liabilities:
Accounts payable	1,375	3,581
Accrued expenses	3,449	9,754
Lease liabilities, current	133	44
Total current liabilities	4,957	13,379
Royalty purchase liability	151,049	139,635
Lease liabilities, net of current portion	1,117	0
Deferred tax liability	203	203
Total liabilities	157,326	153,217
Commitments (Note 9)
Stockholders’ Equity:
Preferred stock, $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding.	0	0
Common stock, $0.001 par value: 200,000,000 shares authorized; 54,392,170 and 28,510,066 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	54	28
Additional paid-in capital	306,167	269,137
Accumulated other comprehensive loss	0	(22)
Accumulated deficit	(437,406)	(378,324)
Total stockholders’ equity	(131,185)	(109,181)
Total liabilities and stockholders' equity	$ 26,141	$ 44,036

About Galera Therapeutics Inc

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.

CEO	Dr. J. Mel Sorensen M.D.
WEBSITE	galeratx.com
INDUSTRY	Biotechnology
EMPLOYEES	31

Galera Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Galera Therapeutics Inc? What does GRTX stand for in stocks?

GRTX is the stock ticker symbol of Galera Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Galera Therapeutics Inc (GRTX)?

As of Fri Apr 19 2024, market cap of Galera Therapeutics Inc is 9.79 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GRTX stock?

You can check GRTX's fair value in chart for subscribers.

What is the fair value of GRTX stock?

You can check GRTX's fair value in chart for subscribers. The fair value of Galera Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Galera Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GRTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Galera Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether GRTX is over valued or under valued. Whether Galera Therapeutics Inc is cheap or expensive depends on the assumptions which impact Galera Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GRTX.